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Synopsis 
The implementation of electronic prescribing and medication administration systems (EPMAs) is a 
priority for hospitals and a potential component of antimicrobial stewardship (AMS). 
Objectives 
This study aimed to identify software features within EPMAs that could potentially facilitate AMS 
and to survey practising UK infection specialist healthcare professionals in order to assign priority to 
these software features. 
Methods 
A questionnaire was developed using nominal group technique and transmitted via email links 
through professional networks. The questionnaire collected demographic data, information on 
priority areas and anticipated impact of EPMA. Responses from different respondent groups were 
compared using the Mann Whitney U test. 
Results 
Responses were received from 164 individuals (142 analysable). Respondents were predominantly 
specialist infection pharmacists (48%) or medical microbiologists (37%). 59% of pharmacists had 
experience of EPMA in their hospitals compared to 35% of microbiologists. Pharmacists assigned 
higher priority to: indication prompt (p<0.001), allergy checker (p=0.003) treatment protocols 
(p=0.003), drug-indication mismatch alerts (p=0.031) and prolonged course alerts (p=0.041); and 
lower priority to a dose checker for adults (p=0.02) and an interaction checker (p<0.05), than 
microbiologists. A “soft stop” functionality was rated essential or a high priority by 89% of 
respondents. Potential EPMA software features were expected to have the greatest impact on 
stewardship, treatment efficacy and patient safety outcomes with lowest impact on Clostridium 
difficile infection (CDI), antimicrobial resistance and drug expenditure. 
Conclusions 
The survey demonstrates key differences in health professionals’ opinions of different healthcare 
benefits of EPMA but a consensus of anticipated positive impact on patient safety and antimicrobial 
stewardship.  
INTRODUCTION 
Antimicrobial resistance (AMR) is a major threat to public health and a significant resource and cost 
burden on the United Kingdom (UK) National Health Service (NHS).1 The Chief Medical Officer’s 2013 
report on infections and the rise of AMR called for action to preserve the effectiveness of existing 
antimicrobials through antimicrobial stewardship (AMS).1 The 2013 UK Five Year Antimicrobial 
Resistance Strategy from the Department of Health (DH) also highlights AMS as one of seven key 
areas for action and NHS England has subsequently introduced antimicrobial prescribing reduction 
goals for English hospitals through the Commissioning for Quality and Innovation (CQUIN) 
programme for 2016/17.2, 3   
 
In 2012, the UK Department of Health commissioned a study of the potential benefits to staff and 
patients of greater use of digital and information technology in the NHS and social care.4  The study 
report identified four priority actions, one of which was to drive the rollout and use of electronic 
prescribing (e-prescribing) in secondary care.  Implementation of e-prescribing systems in hospitals 
presents a unique opportunity to improve the quality of antimicrobial prescribing and to facilitate 
AMS.5-10  Evidence for the benefits of AMS functionality within e-prescribing systems comes from 
published research studies demonstrating positive impact on outcomes including increased guideline 
adherence11, 12 and effective initial therapy13 or reductions in antimicrobial prescribing,14, 15  
resistance,16, 17 dosing errors,8 length of hospital or ICU stay14, 18 and mortality.12, 13, 19  However, 
many of these information systems were created on a small scale in individual hospitals or groups of 
institutions and few reports cover the full potential range of software features that enable AMS.  
Moreover there does not appear to be a recognised standard to guide the specification and 
commissioning of an optimal e-prescribing system that includes the required AMS functionality 
appropriate for the challenges that health systems currently face worldwide.20 
 
This report presents results from a cross-sectional survey of UK infection specialist health 
professionals. The specific objectives of this study were: to identify, using a convenience sample of 
local infection experts (the nominal group technique), software features within NHS hospital e-
prescribing systems that could potentially facilitate antimicrobial stewardship; to assign a priority to 
these software features according to the opinions of practising infection specialist healthcare 
professionals; to identify any differences in priority setting according to professional group, hospital 
status (teaching or district general) or previous experience of e-prescribing systems; and to 
communicate research findings to e-prescribing software manufacturers and healthcare policy 
makers. 
 
MATERIALS AND METHODS 
Two focus group meetings of experienced infection health professionals from a local network of 
hospitals in the south central region of England were convened in order firstly, to identify software 
features within existing e-prescribing and medicines administration (EPMA) systems that facilitate 
AMS and secondly, to identify additional software features with the potential to facilitate AMS. The 
focus groups had representation from six infection hospital pharmacists (three with experience of 
EPMA systems), two consultant medical microbiologists (one with experience of EPMA systems) and 
one EPMA analyst.  The focus group meeting output was a list of software features to be included in 
a questionnaire for wider circulation among UK infection specialist health professionals.  Following 
the focus groups, two infection pharmacists designed a questionnaire using SurveyMonkey® 
software.  The questionnaire included 42 questions, which were divided into 4 domains. The first 
domain collected respondent demographic data including professional group, experience in a 
specialist role, hospital setting and EPMA experience.  In the remaining three domains, respondents 
were asked to assign a priority to individual software features grouped according to the categories 
of prescribing alerts/prompts (12 features), active prescription surveillance (11 features) and 
prescribing trend surveillance (8 features).  At the end of each domain, respondents were asked to 
express their opinion of the anticipated collective impact of the software features from each domain 
on a number of clinical, microbiological and process outcomes. For the prescribing trend surveillance 
domain, respondents were asked to prioritise a number of technical aspects of the proposed 
surveillance reports.  Finally, the questionnaire provided a freetext narrative section inviting 
respondents to suggest additional software features with potential to facilitate AMS, not mentioned 
earlier in the survey.  The questionnaire was piloted in the local region, predominately with infection 
pharmacists and one medical microbiologist in October 2014.  Feedback from the pilot led to the 
incorporation of one additional category (work efficiency) to the list of process outcomes. A copy of 
the finalised questionnaire and covering letter to respondents is available as an online Supplement 
(S1).   
 
Respondents were advised that participation was voluntary and anonymous, that the questionnaire 
would take approximately 10-12 minutes to complete and that the results would be disseminated to 
e-prescribing software manufacturers, policy makers and the clinical infection community.  The 
research team took the decision not to collect personal details of respondent names and employers 
in order to elicit candid responses; although respondent internet protocol (IP) addresses were 
collected, identifying responses from the same healthcare organisations.   A hyperlink to the online 
questionnaire was distributed via health professional networks including the UK Clinical Pharmacy 
Association, the Royal College of Pathologists, the British Society for Antimicrobial Chemotherapy 
and Public Health England. The online questionnaire was closed in July 2015, 7 months from launch.  
Table 1 presents a glossary of key terms used in the questionnaire that will be referred to 
throughout this report. 
 
Analysis methods 
Questionnaire data were summarised with descriptive statistics and analysed using IBM SPSS v.22 
with priority ranking of software features by different groups of respondents compared using the 
Mann Whitney U test. The respondent groups compared were: specialist pharmacists versus medical 
microbiologists (the number of respondents from other professional groups was too few for 
statistical analysis); respondents from hospitals with EPMA experience versus those without; and 
respondents from teaching hospitals versus district general hospitals (DGHs). A p-value of <0.05 was 
considered statistically significant.  Finally, the freetext narrative comments were analysed by using 
a summative approach to qualitative content analysis, grouping responses into common themes 
according to frequency of reporting.21  
 
This research did not require NHS Research Ethics Committee approval for sites in England, Scotland, 
Wales or Northern Ireland according to the Health Research Authority online decision tool 
(http://www.hra-decisiontools.org.uk/ethics/). 
 
RESULTS 
Respondent accountability 
Responses were received from 164 individuals from 79 unique IP addresses. Twenty-two response 
sets were removed from the dataset (11 pharmacists, 6 medical microbiologists, one ID physician, 4 
nurses and one trainee) due to failure to complete responses to survey questions beyond 
demographics. Responses from the remaining 142 individuals from 68 unique IP addresses were 
included in the analysis. Eleven of these 142 did not complete all sections of the questionnaire and 
missing data were ignored as they comprised less than 10% of responses. 
 
Respondent demographics 
The demographic profile of the 142 respondents included in the analysis is presented in Figure1. 
Infection pharmacists comprised almost half of respondents (48%; 68/142) from 39 IP addresses and 
the majority had at least 5 years’ experience in a specialist infection role (47/68).   Medical 
microbiologists represented over one-third of respondents (37%; 53/142) from 35 IP addresses and 
most had at least 5 years’ experience (48/53).  Six infectious diseases (ID) physicians responded to 
the survey and a further six respondents were grouped as other healthcare professionals (medical 
virologist, epidemiologist, junior doctor, infection prevention nurse, surveillance nurse and a 
consultant in public health). 
 
Fifty-two per cent of respondents were from DGHs (71/136 responses) and 45% from teaching 
hospitals (61/136 responses).  Figure 2 illustrates the distribution of experience of EPMA and e-
prescribing systems amongst the questionnaire respondents.  Half of respondents (49%; 68/139) 
reported experience of EPMA or e-prescribing; 59% of 68 infection pharmacists had experience of 
EPMA in their hospitals compared to 35% of 52 microbiologists. Forty per cent (56/139) expected 
implementation of EPMA within 5 years (25 from teaching hospitals and 29 from district general 
hospitals) but 11% (15/139) did not expect EPMA within 5 years (5 from teaching hospitals and 9 
from district general hospitals). 
 
Prescribing Prompt Software Features 
Table 2 presents survey response data for priority attributed by respondents to 12 software features 
of EPMA systems grouped within the Prescribing Prompt category.  With the exception of restriction 
features, all prescribing prompt software features were considered essential or high-priority by the 
majority (>50%) of respondents. The features considered essential by more than 50% of respondents 
were: an allergy checking function and a prompt to prescribers to record the clinical indication for 
prescribing an antimicrobial.  
 
In comparison with medical microbiologists, specialist pharmacists assigned higher priority to: 
indication prompt (p<0.001); allergy checker (p=0.003); and treatment protocols (p=0.003) (Table 3).  
Medical microbiologists assigned higher priority to a dose checker for adults (p=0.023) and an 
interaction checker (p<0.05).   Respondents from hospitals with EPMA experience assigned higher 
priority to an indication prompt (p=0.049); whereas respondents from hospitals without EPMA 
experience assigned higher priority to: restricted antimicrobial block (p=0.011); dose checker for 
children (p=0.024); and blood level monitoring alert (p=0.033). When responses from teaching 
hospitals were compared with responses from DGHs, there were no statistically significant 
differences in opinions of priority for any of the prescribing prompt software features.  The majority 
of respondents considered that both patient safety (60%; 84/140) and ability to deliver antimicrobial 
stewardship (64%; 89/140) were extremely likely to be improved (Figure 3). 
 
Active Prescription Surveillance Software Features 
Table 4 presents survey response data for priority attributed by respondents to 11 software features 
of EPMA systems grouped within the Active Prescription Surveillance category.  All but two of the 11 
features (daily reports of new or ongoing prescriptions of all antimicrobials) were considered 
essential or high priority by the majority (>50%) of respondents. Only one feature was considered 
essential by more than 50% of respondents: daily report of new prescriptions for critical 
antimicrobials.   
 
Specialist pharmacists assigned higher priority to a daily report of mismatch between prescribed 
antimicrobial and associated indication (p=0.031) and long IV/oral courses (p=0.041) in comparison 
to medical microbiologists (Table 3).  Respondents from hospitals with EPMA experience (in 
comparison to those without) assigned higher priority to: a daily report of newly-prescribed critical 
antimicrobials (p=0.015); and a daily report of any newly-prescribed antimicrobial (p=0.024). When 
responses from teaching hospitals were compared with responses from DGHs, there were no 
statistically significant differences in opinions of priority for any of the active prescription 
surveillance software features.  The majority (>50%) of respondents considered that both patient 
safety (53%; 71/135) and ability to deliver antimicrobial stewardship (60%; 80/134) were extremely 
likely to be improved (Figure 4). Two respondents expressed the view that an improvement in 
outcomes was extremely unlikely: one for reduction in expenditure on drugs; and one for reduction 
in risk of Clostridium difficile. 
 
Prescribing Trend Surveillance Software Features 
Prescribing trend surveillance reports as a software feature were generally considered by 
respondents to be of lower priority compared with prescribing prompts and active prescription 
surveillance, with no trend surveillance software feature rated as essential by more than 50% of 
respondents (Table 5).  However, the majority of respondents did consider all of the proposed trend 
surveillance features to be at least high priority.  There were no statistically significant differences in 
opinions of priority for prescribing trend surveillance software features between specialist 
pharmacists and medical microbiologists, nor between respondents with or without EPMA 
experience.  Respondents from DGHs assigned a higher priority to the report of trends in proportion 
of stat doses where administration was delayed software feature (p=0.034) (Table 3).  The majority 
of respondents considered that the prescribing trend surveillance group of software features would 
be likely or extremely likely to have a positive impact on all of the listed clinical, microbiological and 
process outcomes (Figure 5). More than 90% of respondents anticipated a positive impact on their 
ability to deliver AMS. 
 
Respondent opinions of selected technical aspects of prescribing trend surveillance reporting are 
summarised in Table 6.  Respondents expressed equal preference for patient days or patient 
admissions as an activity denominator. A preference for annual and quarterly reporting intervals 
rather than more frequent reports was evident.  Surveillance reports for the whole hospital and by 
clinical speciality or hospital department were rated more highly than reports by hospital ward or 
individual responsible consultant physician. Finally, surveillance reports of prescribing and 
administration of individual antimicrobials, by antimicrobial drug class and by locally defined drug 
groups such as broad-spectrum agents were rated most highly by respondents with reports grouped 
by route of administration considered of lesser importance. 
 
Freetext narrative responses 
Thirty-five respondents recorded narrative responses when prompted to submit suggestions for 
additional software features not included in the questionnaire and 69 unique statements were 
identified and grouped into nine common themes, presented in Table 7. Eighteen respondents 
suggested an interface with other electronic systems for previous and current microbiology 
investigations and results and for drug and clinical information to guide prescribing. There was an 
apparent demand for flexibility in reporting software to allow reports to be customised locally but 
also to generate a standard set of reports for reporting to Public Health England in accordance with 
antimicrobial stewardship guidance for English Hospitals: Start Smart – Then Focus.22 
 
DISCUSSION 
This is the first survey of UK infection specialist healthcare professionals evaluating opinions of the 
potential for e-prescribing software to facilitate antimicrobial stewardship.  The two largest health 
professional groups responsible for AMS are represented and the majority of respondents were 
experienced in a specialist role. We estimate an approximate response rate of 24% of NHS hospital 
specialist infection pharmacists and at least 8% of practising UK medical microbiologists.23, 24 
Responses were included from 68 unique IP addresses representing up to 36% (68/188) of NHS 
hospital trusts/boards if the questionnaire was completed from the employing hospital’s IP 
address.25-28  Teaching hospitals are proportionately over-represented compared with DGHs but 
there was a good balance of respondents with experience of EPMA systems and those without. 
 
The prescribing prompt software features ranked of highest priority by respondents were allergy 
checker, interaction checker and dose checker, which are already incorporated as standard 
functionality in a number of existing EPMA systems in NHS hospitals.29  The response data suggest an 
unmet need for AMS-relevant features such as recording of indication and “soft stop” functionality; 
that are not routinely incorporated into existing EPMA systems.  The responses suggest relatively 
little appetite among UK infection specialists for software features to support restriction of 
prescribing of selected antimicrobials, possibly reflecting the inter-speciality conflict inherent in such 
policies, resource implications and the lack of longer-term superiority over persuasive 
interventions.30  Priorities for active prescription surveillance software features were divided 
between an emphasis on patient safety (drug-indication mismatch and missed doses) and 
stewardship (prescriptions for critical antimicrobials and long course lengths).  Reports of new or 
ongoing prescriptions of any antimicrobial were considered lower priority, potentially reflecting the 
limited resources available to AMS teams to review these prescriptions.31  Opinions of the expected 
impact of the proposed prescribing prompt and active prescription surveillance software features on 
patient outcomes, public health outcomes and resource use outcomes were overwhelmingly 
positive.  It is particularly striking that more than 90% of respondents considered prescribing prompt 
software features and active prescription surveillance features either likely or extremely likely to 
improve patient safety, corroborated by an expectation of improved treatment efficacy and reduced 
Clostridium difficile infection.  An improvement in ability to deliver stewardship and more efficient 
deployment of stewardship resources was also anticipated. 
 
We found that pharmacists were more likely to prioritise a prescribing prompt to record indication, 
which may reflect the uncertainty faced by hospital pharmacists when validating new prescriptions 
for antimicrobials (for safety and effectiveness) prior to authorising dispensing; and the requirement 
to audit antimicrobial prescribing for adherence to local treatment guidelines.22, 32 Pharmacists also 
prioritised the treatment protocol software feature, consistent with their preference for daily 
reports of drug-indication mismatch in contrast to medical microbiologists.  We found that medical 
microbiologists were more likely to prioritise prescribing prompts for dose checking and interaction 
checking in comparison to pharmacists, perhaps indicating differences in undergraduate teaching 
and endorsing the value of a multi-disciplinary approach to infection management.  Respondents 
from hospitals with experience of EPMA systems ranked the indication prompt feature as relatively 
more important in comparison to those without, suggesting an unmet need amongst existing 
software systems.   
 
When technical aspects of surveillance reports were considered, it is of interest that reports by 
individual responsible consultant physician were considered of lesser importance than reports by 
clinical speciality or hospital department.  This finding suggests a lack of willingness to employ a 
“name-and-shame” approach to stewardship and may represent a preference for promoting a sense 
of collective responsibility amongst clinician colleagues.  Freetext comments identified strong user 
demand for an interface with the microbiology laboratory software system to support selection of 
effective therapy and de-escalation and to facilitate prompt intervention when patients are 
prescribed potentially ineffective therapy. 
 
This cross-sectional survey was designed in accordance with recommended principles of health 
professional survey design as far as possible within the available resources.33, 34  However, a shorter 
questionnaire may have improved the response rate.33  The exclusion of data relating to address or 
employer means that we cannot rule out the possibility that multiple responses may have been 
submitted by the same individuals and it is likely that multiple respondents from the same Trust had 
an effect on our findings.  We were also unable to collect information on non-responders so the 
respondent sample is likely to be biased towards more motivated individuals who are engaged with 
quality improvement and/or information technology. Approximately half of respondents reported 
experience of EPMA or e-prescribing and this suggests a potential bias towards hospitals with such 
systems when compared with a survey carried out by Public Health England in 2014 which reported 
only 17/76 (22%) of respondent hospitals with e-prescribing for at least one inpatient area.35 The 
questionnaire did not specifically elicit a description of the existing software features of EPMA 
systems currently installed in NHS hospitals but anecdotal evidence from the research team and 
from professional networks in the UK suggests that software features to support AMS are extremely 
limited.  Some of the software features proposed in this survey may not be technically possible for 
existing e-prescribing systems and separate data-mining software may be required, particularly for 
prescribing trend surveillance.  Finally, the present questionnaire was primarily distributed by e-mail 
to members of professional organisations and therefore may not represent the views of non-
members. 
 
The target audience for this survey – consultant medical microbiologists and specialist pharmacists – 
was deliberate, to focus on individuals most likely to be responsible for stewardship within an NHS 
hospital organisation.  However, other healthcare workers also play an important role in AMS at the 
individual patient level including junior and senior doctors, nurses, non-medical prescribers and 
ward pharmacists.36-41 Inclusion of these professional groups in user-testing at the design stage of 
EPMA implementation is likely to be critical to the success of the proposed software features. Future 
surveys focussing on front-line prescribers and medication administrators are critical. 
 
The advent of e-prescribing to NHS hospitals represents a unique new opportunity to engage with 
healthcare professionals to promote safe, effective and proportionate antimicrobial prescribing and 
to refresh the antimicrobial stewardship message. It must be acknowledged however that with this 
opportunity also comes new threats to patient safety from prescribing and administration errors as 
well as potential de-skilling of healthcare professionals.42-44   The judicious use of educational 
prompts may facilitate a sustained change in prescribing behaviour but this must be balanced 
against the recognised risk of “alert fatigue” and competing priorities for e-prescribing system 
functionality from other medical and surgical specialities.45  Successful implementation of the 
proposed antimicrobial stewardship software features into e-prescribing systems will likely be 
contingent upon a variety of sociotechnical considerations including seamless integration into the 
prescribing workflow with minimal time penalties for end-users and full compatibility with existing 
NHS information technology hardware and software.43, 46   
 
This survey represents the first attempt to canvas opinion of infection specialists in the UK on the 
potential for e-prescribing software to support antimicrobial stewardship.  The findings illustrate 
fundamental principles that are equally relevant to health systems in other countries. The survey 
results reveal considerable demand for additional software features expressed by the healthcare 
professionals charged with promoting rational use of antimicrobials and a consensus of anticipated 
positive impact on patient safety and efficiency outcomes. The survey demonstrates key differences 
in health professionals’ opinions of different healthcare benefits of EPMA and underscores the need 
for a multi-disciplinary approach to the development of EPMA system specifications. We trust this 
information will prove valuable to software manufacturers currently developing e-prescribing 
systems when prioritising software functionality and systems interface development and potentially 
to healthcare commissioners when drafting e-prescribing system specifications. Finally, we 
commend this topic to research funders with a view to funding research into the potential benefits 
and unintended consequences of e-prescribing system functionality designed to support 
antimicrobial stewardship. 
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Table 1.  Glossary of key terms used in the survey of opinions of infection specialists on electronic 
prescribing and antimicrobial stewardship 
Term Explanation 
Prescribing alert / 
prompt 
The prescriber will be alerted via a “pop-up” message – an “alert or 
prompt” – e.g. if attempting to prescribe an antimicrobial which is contra-
indicated because of an allergy or a drug interaction 
Active prescription 
surveillance 
Active prescription surveillance refers to the application of surveillance 
data in real-time for identification of patients currently prescribed 
antimicrobial therapy.  Software features allow prioritisation of patients 
for intervention by the antimicrobial stewardship team (AST). 
Active prescription surveillance reports would typically include: patient 
name, date of birth, hospital number, inpatient location in the hospital, 
drug name, drug dose, start date, stop date (if specified), prescriber and 
responsible senior physician. 
Prescribing trend 
surveillance 
Prescribing trend surveillance refers to the review of retrospective data 
relating to antimicrobial prescribing and administration – typically as 
trends over time. Prescribing trend surveillance allows continuous 
monitoring of performance for the purposes of controls assurance and for 
evaluating the impact of stewardship interventions. 
Order Sets This software feature allows the prescriber to select an infection (e.g. 
pneumonia, community-acquired, severe) and the system will 
automatically populate the prescription with the locally pre-defined 
treatment regimen (single drug or combination of drugs) at standard 
doses. 
Critical antimicrobial An antimicrobial may be designated “critical” by a hospital AST according 
to local priorities – for example, broad-spectrum antimicrobials such as 
carbapenems or antimicrobials with a narrow therapeutic range such as 
colistin. A prescriber may be alerted when prescribing a critical 
antimicrobial with an appropriate locally-defined message containing 
details of actions required when prescribing. 
Restricted 
antimicrobial 
An antimicrobial may be designated “restricted” by a hospital AST on 
grounds of financial cost, propensity to predispose to Clostridium difficile 
infection or local decision to reserve for multidrug-resistant infections. 
Prescribing of restricted antimicrobials requires pre-authorisation by a 
medical microbiologist or infectious diseases physician (“restricted 
antimicrobial authorisation”) or prescribing is limited by the prescribing 
software to senior clinicians (“restricted antimicrobial block”). 
Soft Stops This software feature allows the prescriber to nominate a date when the 
antimicrobial prescription should be reviewed with a view to stopping, 
changing treatment or switching route of administration to oral. After the 
review date has passed, the drug will remain visible and available to 
nursing staff to administer but will be prominently highlighted as being 
past the review (soft stop) date 
Blood level monitoring 
order set 
When a relevant drug is prescribed, the EPMA system will automatically 
pair the drug prescription with an order for a blood specimen to be taken 
at an appropriate time post-dose. 
Drug-indication 
mismatch 
A mismatch occurs when a prescribed antimicrobial is not appropriate or 
unauthorised for the recorded indication/provisional diagnosis. 
Days of Therapy (DOTs) One DOT represents the administration of a single systemic antimicrobial 
on a given day regardless of the number of doses administered or dosage 
strength. For example, administration of ceftriaxone as 4g once-daily or as 
2g twice-daily for one day would both represent 1 DOT. A single patient 
receiving both vancomycin and ceftazidime during the same day would be 
recorded as receiving 2 DOTs (1 of vancomycin and 1 of ceftazidime).47   
Length of Therapy 
(LOT) 
LOT refers to antimicrobial course length and is the number of sequential 
days that a patient receives any systemic antimicrobial drug(s), 
irrespective of the number of different drugs.47  A prescription of 
intravenous piperacillin-tazobactam and vancomycin for 2 days followed 
by oral co-amoxiclav for 5 days corresponds to a LOT of 7 days. 
Point Prevalence Point prevalence is the proportion of hospital patients active on the EPMA 
system that are prescribed any antimicrobial at a specific point in time 
(for example at noon on the first day of each month). 
 
  
   
  
  
Table 2.  Prescribing Prompt software features ranked in order of respondent-assigned priority 
Software 
feature 
Number of 
responses 
Essential 
High 
priority 
Medium 
priority 
Low 
priority 
Not a 
priority 
Allergy 
checker 
142 80.3% 14.8% 3.5% 1.4% 0.0% 
Indication 
prompt 
139 56.8% 30.9% 10.8% 1.4% 0.0% 
Interaction 
checker 
143 45.5% 35.7% 14.7% 4.2% 0.0% 
Soft stop 
141 38.3% 51.1% 7.1% 2.8% 0.7% 
Blood level 
prompt 
140 35.0% 46.4% 15.7% 2.9% 0.0% 
Dose checker 
(children) 
142 33.8% 44.4% 19.0% 2.1% 0.7% 
Dose checker 
(adults) 
141 25.5% 48.2% 22.0% 3.5% 0.7% 
Critical 
antimicrobial 
prompt 
141 24.1% 48.2% 21.3% 4.3% 2.1% 
Indication 
order set 
143 21.7% 45.5% 25.2% 4.9% 2.8% 
Blood level 
order set 
140 21.4% 39.3% 29.3% 9.3% 0.7% 
Restricted 
antimicrobial 
require 
authorisation 
142 18.3% 25.4% 30.3% 17.6% 8.5% 
Restricted 
antimicrobial 
block by 
prescriber 
140 15.7% 31.4% 26.4% 16.4% 10.0% 
 
  
Table 3.  Differences in software feature priority assignment between respondent groups found to 
be statistically significant 
Domain / 
Respondent 
group 
Software feature Respondent group (% of 
responses rated essential) 
Mann-
Whitney U 
test p-value 
Professional 
group 
 Pharmacists Medical 
microbiologists 
 
Prescribing 
prompts 
Allergy checker 90% 69% p=0.003 
(n=68, 52) 
Indication prompt 73% 39% p<0.001 
(n=67, 51) 
Treatment protocols 28% 15% p=0.003 
(n=68, 53) 
Dose checker (adults) 16% 34% p=0.023 
(n=68, 53) 
Interaction checker 34% 51% p=0.047 
(n=68, 53) 
Active 
prescription 
surveillance 
Drug-indication mismatch 35% 25% p=0.031 
(n=65, 49) 
Long IV/oral course 31% 24% p=0.041 
(n=65, 50) 
EPMA 
experience 
 EPMA-
experienced 
Non EPMA-
experienced 
 
Prescribing 
prompts 
Indication prompt 66% 47% p=0.049 
(n=68, 68) 
Restricted antimicrobial block 12% 17% p=0.011 
(n=67, 70) 
Dose checker (children) 26% 39% p=0.024 
(n=68, 70) 
Blood level monitoring alert 24% 44% p=0.033 
(n=67, 70) 
Active 
prescription 
Daily report of newly-prescribed 
critical antimicrobials 
64% 40% p=0.015 
(n=64, 68) 
surveillance Daily report of any newly-
prescribed antimicrobial 
23% 16% p=0.024 
(n=64, 68) 
Hospital type  Teaching District 
General 
 
Prescribing 
trend 
surveillance 
Report of trends in proportion of 
stat doses where administration 
was delayed 
28% 18% p=0.034 
(n=55, 65) 
 
  
Figure 3.  Respondent opinions of the likely impact of Prescribing Prompt software features  
on clinical, microbiological and process outcomes 
 
 
  
Table 4.  Active Prescription Surveillance software features ranked in order of respondent-
assigned priority 
Software 
feature 
Number of 
responses 
Essential 
High 
priority 
Medium 
priority 
Low 
priority 
Not a 
priority 
New Rx of 
critical drug 
135 51.9% 41.5% 6.7% 0.0% 0.0% 
Ongoing Rx of 
critical drug 
135 42.2% 42.2% 15.6% 0.0% 0.0% 
Drug-indication 
mismatch 
134 31.3% 47.8% 17.9% 3.0% 0.0% 
Long IV/oral 
course 
135 28.9% 54.8% 14.8% 0.7% 0.7% 
Missed Abx 
doses 
132 26.5% 43.9% 22.7% 6.1% 0.8% 
Long IV course 132 25.0% 59.8% 14.4% 0.8% 0.0% 
High-dose 
aminoglycoside 
133 23.3% 40.6% 25.6% 9.0% 1.5% 
New Rx for 
sepsis of 
unknown origin 
134 20.1% 57.5% 19.4% 1.5% 1.5% 
New Rx of any 
antibiotic 
136 19.1% 27.9% 33.1% 17.6% 2.2% 
Ongoing Rx of 
any antibiotic 
133 13.5% 30.8% 36.1% 15.0% 4.5% 
New Rx for  
diagnosis of 
interest 
135 13.3% 51.9% 30.4% 3.0% 1.5% 
 
 
  
Figure 4. Respondent opinions of the likely impact of Active Prescription Surveillance software 
features on clinical, microbiological and process outcomes 
 
  
Table 5.  Prescribing Trend Surveillance software features ranked in order of respondent-assigned 
priority 
Software 
feature 
Number of 
responses 
Essential 
High 
priority 
Medium 
priority 
Low 
priority 
Not a 
priority 
Trends in 
point 
prevalence 
130 29.2% 44.6% 23.1% 2.3% 0.8% 
Trends in 
missed 
doses 
130 26.9% 45.4% 24.6% 2.3% 0.8% 
Trends in 
delayed stat 
doses 
130 23.1% 53.8% 19.2% 3.8% 0.0% 
Trends in 
total days of 
therapy 
(DOTs) 
130 13.1% 39.2% 37.7% 7.7% 2.3% 
Trends in 
average 
length of 
therapy 
(LOT) 
131 13.0% 53.4% 29.0% 3.8% 0.8% 
 
 
  
Figure 5:  Respondent opinions of the likely impact of Prescribing Trend Surveillance software 
features on clinical, microbiological and process outcomes 
 
  
Table 6: Respondent opinions of technical aspects of prescribing trend surveillance reporting 
software features ranked in order of respondent-assigned priority 
 Response 
Count 
Importance attributed by respondents 
Very high High Moderate Some None 
ACTIVITY DENOMINATOR 
EPMA patient 
days (total 
number of 
patients 
multiplied by 
number of 
days) 
130 16.2% 40.0% 31.5% 10.8% 1.5% 
EPMA 
admissions 
(new patients) 
130 13.8% 38.5% 36.2% 10.8% 0.8% 
REPORT TIME INTERVALS 
Annually 130 48.5% 31.5% 13.1% 3.8% 3.1% 
Quarterly 130 40.0% 42.3% 13.8% 2.3% 1.5% 
Monthly 130 24.6% 36.9% 29.2% 6.9% 2.3% 
Weekly 129 7.8% 20.9% 27.9% 28.7% 14.7% 
Daily 130 4.6% 15.4% 22.3% 26.2% 31.5% 
HOSPITAL SUBDIVISIONS 
Whole hospital 129 49.6% 38.8% 6.2% 4.7% 0.8% 
Clinical 
speciality 
128 42.2% 41.4% 11.7% 3.9% 0.8% 
Hospital 
departments 
128 40.6% 36.7% 16.4% 4.7% 1.6% 
Wards 128 32.8% 39.1% 21.1% 5.5% 1.6% 
Responsible 
consultant 
physician 
129 32.6% 37.2% 20.2% 9.3% 0.8% 
DRUG GROUPINGS 
Individual 
drugs 
129 48.8% 36.4% 10.9% 2.3% 1.6% 
Drug class (e.g. 
macrolides) 
128 41.4% 41.4% 13.3% 3.9% 0.0% 
Locally-defined 
drug group 
(e.g. broad-
spectrum, 
narrow-
spectrum) 
130 40.0% 38.5% 16.9% 4.6% 0.0% 
Antibacterials, 
antifungals, 
antivirals, 
antiparasitics 
127 33.9% 37.0% 15.7% 13.4% 0.0% 
All 
antimicrobials 
130 30.0% 36.9% 19.2% 11.5% 2.3% 
By route of 
administration 
129 24.0% 40.3% 24.8% 8.5% 2.3% 
 
 
  
Table 7.  Thematic analysis of freetext narrative responses to the question: “Do you have any 
other suggestions for potential functionality for electronic prescribing and medicines 
administration systems?” 
Theme Frequency Details of additional user requirements 
Microbiology laboratory system 
interface 
13  Susceptibility testing – prescription conflict 
(“drug-bug mismatch”) 
 Previous microbiology including healthcare-
associated infections 
Reporting functions 9  Flexibility of reporting – capacity to customise 
reports locally 
 Reporting to national standard (Start Smart – 
Then Focus) 
 Defined daily doses in addition to DOTs 
Clinical information system 
interface 
5  Link to guidelines 
 Drug information: adverse effects, drug 
administration, drug monitoring 
 Disease severity scoring systems 
Restriction systems 5  Authorisation codes 
 Authorisation by named specialist 
 System access restricted to trained prescribers 
 Compulsory recording of indication 
Additional narrative fields 5  Infection specialist advice 
 Justification for off-guideline prescribing 
 Precise nature of drug allergy 
 Reasons for missed doses 
Soft stops / review dates 4  Block administration until review 
 Patient safety of automatic prescription stop 
Dosing support 3  Dosing by age, weight and renal function 
Drug history 3  Primary care and previous hospital admissions 
Stat doses 3  Automatic associated stat dose and 
appropriately spaced maintenance dose 
 Stat dose remains visible if delayed 
Miscellaneous 19  
 
 
